X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (222) 222
humans (192) 192
hepatitis c (180) 180
hepatitis c virus (171) 171
gastroenterology & hepatology (153) 153
interferon-free therapy (133) 133
antiviral agents - therapeutic use (123) 123
ribavirin (121) 121
hepatitis c, chronic - drug therapy (114) 114
interferon-free (107) 107
interferon (103) 103
sustained virological response (98) 98
hepatitis (89) 89
sofosbuvir (89) 89
antiviral agents (78) 78
hepacivirus - genetics (78) 78
male (74) 74
female (71) 71
biological response modifiers (70) 70
genotype (70) 70
hcv (68) 68
direct-acting antivirals (67) 67
middle aged (67) 67
virus-infection (65) 65
cirrhosis (63) 63
treatment outcome (61) 61
hepacivirus - drug effects (59) 59
drug therapy, combination (56) 56
health aspects (55) 55
liver (52) 52
treatment-naive patients (52) 52
pharmacology & pharmacy (48) 48
sustained virologic response (48) 48
genotype 1 infection (47) 47
hepatitis c - drug therapy (47) 47
hepatitis c, chronic - virology (47) 47
antiviral agents - adverse effects (46) 46
drug therapy (45) 45
infection (44) 44
therapy (44) 44
infections (43) 43
infectious diseases (42) 42
aged (41) 41
hepatocellular carcinoma (41) 41
hepatology (40) 40
liver cirrhosis (40) 40
patients (40) 40
adult (38) 38
ribavirin - therapeutic use (38) 38
viruses (38) 38
antiviral agents - administration & dosage (36) 36
chronic hepatitis-c (36) 36
plus ribavirin (36) 36
interferon-free regimens (35) 35
hepatocellular-carcinoma (34) 34
gastroenterology and hepatology (33) 33
virus diseases (33) 33
protease inhibitors (32) 32
recurrence (32) 32
care and treatment (31) 31
analysis (30) 30
daclatasvir (30) 30
hepatitis c, chronic - complications (30) 30
fibrosis (29) 29
antiviral agents - pharmacology (28) 28
antiviral therapy (28) 28
chronic hepatitis c (28) 28
genotype 1 (28) 28
hepatitis-c virus (28) 28
liver transplantation (28) 28
interferon-free regimen (27) 27
risk factors (27) 27
virology (27) 27
chronic infection (26) 26
genetic aspects (25) 25
ledipasvir (25) 25
digestive system diseases (24) 24
direct-acting antiviral (24) 24
genotype & phenotype (24) 24
immunology (24) 24
liver diseases (24) 24
genotypes (23) 23
hcv infection (23) 23
protease inhibitor (23) 23
research (23) 23
sulfonamides - therapeutic use (23) 23
treatment-experienced patients (22) 22
animals (21) 21
medicine, general & internal (21) 21
pegylated interferon (21) 21
simeprevir (21) 21
viral nonstructural proteins - antagonists & inhibitors (21) 21
virus (21) 21
abridged index medicus (20) 20
liver cancer (20) 20
medical research (20) 20
open-label (20) 20
review (20) 20
telaprevir (20) 20
transplantation (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (353) 353
German (9) 9
Japanese (8) 8
Chinese (5) 5
Spanish (4) 4
Russian (3) 3
Korean (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF HEPATOLOGY, ISSN 0168-8278, 05/2015, Volume 62, Issue 5, pp. 1040 - 1046
Background & Aims: We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in... 
TREATMENT-NAIVE | THERAPY | Direct-acting antiviral | Egyptian | Hepatitis C virus | GASTROENTEROLOGY & HEPATOLOGY | Sofosbuvir | Interferon-free therapy | EPIDEMIOLOGY | Genotype 4
Journal Article
Transplantation Proceedings, ISSN 0041-1345, 03/2018, Volume 50, Issue 2, pp. 631 - 633
Recurrent infection with the hepatitis C virus (HCV) after liver transplantation (LT) is associated with decreased graft and patient survival. Direct-acting... 
SURGERY | INTERFERON-FREE THERAPY | IMMUNOLOGY | SOFOSBUVIR | REGISTRY | TRANSPLANTATION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus,... 
late relapse | interferon-free regimen | asunaprevir | liver cirrhosis | daclatasvir
Journal Article
Journal of Hepatology, ISSN 0168-8278, 04/2018, Volume 68, Issue 4, pp. 646 - 654
Previous studies have reported a high frequency of hepatocellular carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of... 
Cirrhosis | Hepatocellular carcinoma | Direct acting antivirals | Interferon-free therapy | Sustained viral response | VIRUS | THERAPY | ANTIVIRAL TREATMENT | COHORT | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Gastroenterology, ISSN 0016-5085, 03/2018, Volume 154, Issue 4, pp. 989 - 997
There have been reports of reactivation of hepatitis B virus (HBV) infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral... 
ALT | Tolerability | DAA | Immune Suppression | CLEARANCE | INTERFERON-FREE THERAPY | MANAGEMENT | ANTIVIRAL THERAPY | B-VIRUS | IL28B | HEPATITIS-C VIRUS | REACTIVATION | CELL-FUNCTION | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 7/2014, Volume 60, Issue 1, pp. 37 - 45
Journal Article
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, ISSN 0815-9319, 01/2016, Volume 31, Issue 1, pp. 14 - 22
Background and Aim: Daclatasvir combined with asunaprevir is the first all-oral, ribavirin-free treatment of hepatitis C virus genotype 1b infection in Japan.... 
NUCLEOSIDE/NUCLEOTIDE ANALOG | hepatitis C | SOFOSBUVIR | INTERFERON-FREE STRATEGIES | SIMEPREVIR | RIBAVIRIN | asunaprevir | efficacy | daclatasvir | TRIAL | safety | GENOTYPE 1 INFECTION | HCV | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS
Journal Article